Xolair (ZO-lair), the first biologic therapy for moderate to severe persistent asthma

Genentech is now marketing Xolair (ZO-lair), the first biologic therapy for moderate to severe persistent asthma.

Xolair (omalizumab) is an important new option...but only for a select group of patients.

It's only for allergic asthma in patients age 12 and up... when inhaled steroids aren't enough.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote